Histopathological and Clinical Characteristics of Young Patients with Bladder Cancer
BAUS ePoster online library. Brown A. 06/22/21; 319012; p10-4
Disclosure(s): Nothing to declare
Mr. Andrew Brown
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
Urothelial bladder cancer is rare in younger patients and hence there is sparse data regarding pathology, clinical progression and prognosis in this cohort. We present our experience with such patients.
Patients and Methods
Patients aged 50 years and younger at date of diagnosis were included. They were identified via a retrospective review of pathology samples collected between 2016 and 2020. Demographic data, symptoms, stage and grade at initial transurethral resection, risk stratification, recurrence and progression were included.
Results
61 patients with an average age of 42, were included. 77% of patients had visible haematuria and 72% were referred via the 2WW pathway.
At presentation 11 patients (18%) had intermediate and 29 (48%) low risk disease. 13 patients (21%) presented with high-risk disease. 4 went on to have a cystectomy. 7 patients (11%) presented with muscle invasive disease, of which 4 had metastasis. 1 patient (2%) was found to have a metastatic deposit from gastric adenocarcinoma
49 patients with superficial disease were followed up for an average of 4 years and 1 month. 55% experienced on average 1 recurrence (range 0-8) and 2 patients moved up the risk stratification.
Conclusions
The majority of patients (66%) presented with low or intermediate risk non muscle invasive disease, which rarely progressed or recurred. Rates of muscle invasive and high-risk disease were comparable to the literature. Presentation, progression and outcomes appear to mimic older populations and the management of young patients should follow well established pathways.
Urothelial bladder cancer is rare in younger patients and hence there is sparse data regarding pathology, clinical progression and prognosis in this cohort. We present our experience with such patients.
Patients and Methods
Patients aged 50 years and younger at date of diagnosis were included. They were identified via a retrospective review of pathology samples collected between 2016 and 2020. Demographic data, symptoms, stage and grade at initial transurethral resection, risk stratification, recurrence and progression were included.
Results
61 patients with an average age of 42, were included. 77% of patients had visible haematuria and 72% were referred via the 2WW pathway.
At presentation 11 patients (18%) had intermediate and 29 (48%) low risk disease. 13 patients (21%) presented with high-risk disease. 4 went on to have a cystectomy. 7 patients (11%) presented with muscle invasive disease, of which 4 had metastasis. 1 patient (2%) was found to have a metastatic deposit from gastric adenocarcinoma
49 patients with superficial disease were followed up for an average of 4 years and 1 month. 55% experienced on average 1 recurrence (range 0-8) and 2 patients moved up the risk stratification.
Conclusions
The majority of patients (66%) presented with low or intermediate risk non muscle invasive disease, which rarely progressed or recurred. Rates of muscle invasive and high-risk disease were comparable to the literature. Presentation, progression and outcomes appear to mimic older populations and the management of young patients should follow well established pathways.
Introduction
Urothelial bladder cancer is rare in younger patients and hence there is sparse data regarding pathology, clinical progression and prognosis in this cohort. We present our experience with such patients.
Patients and Methods
Patients aged 50 years and younger at date of diagnosis were included. They were identified via a retrospective review of pathology samples collected between 2016 and 2020. Demographic data, symptoms, stage and grade at initial transurethral resection, risk stratification, recurrence and progression were included.
Results
61 patients with an average age of 42, were included. 77% of patients had visible haematuria and 72% were referred via the 2WW pathway.
At presentation 11 patients (18%) had intermediate and 29 (48%) low risk disease. 13 patients (21%) presented with high-risk disease. 4 went on to have a cystectomy. 7 patients (11%) presented with muscle invasive disease, of which 4 had metastasis. 1 patient (2%) was found to have a metastatic deposit from gastric adenocarcinoma
49 patients with superficial disease were followed up for an average of 4 years and 1 month. 55% experienced on average 1 recurrence (range 0-8) and 2 patients moved up the risk stratification.
Conclusions
The majority of patients (66%) presented with low or intermediate risk non muscle invasive disease, which rarely progressed or recurred. Rates of muscle invasive and high-risk disease were comparable to the literature. Presentation, progression and outcomes appear to mimic older populations and the management of young patients should follow well established pathways.
Urothelial bladder cancer is rare in younger patients and hence there is sparse data regarding pathology, clinical progression and prognosis in this cohort. We present our experience with such patients.
Patients and Methods
Patients aged 50 years and younger at date of diagnosis were included. They were identified via a retrospective review of pathology samples collected between 2016 and 2020. Demographic data, symptoms, stage and grade at initial transurethral resection, risk stratification, recurrence and progression were included.
Results
61 patients with an average age of 42, were included. 77% of patients had visible haematuria and 72% were referred via the 2WW pathway.
At presentation 11 patients (18%) had intermediate and 29 (48%) low risk disease. 13 patients (21%) presented with high-risk disease. 4 went on to have a cystectomy. 7 patients (11%) presented with muscle invasive disease, of which 4 had metastasis. 1 patient (2%) was found to have a metastatic deposit from gastric adenocarcinoma
49 patients with superficial disease were followed up for an average of 4 years and 1 month. 55% experienced on average 1 recurrence (range 0-8) and 2 patients moved up the risk stratification.
Conclusions
The majority of patients (66%) presented with low or intermediate risk non muscle invasive disease, which rarely progressed or recurred. Rates of muscle invasive and high-risk disease were comparable to the literature. Presentation, progression and outcomes appear to mimic older populations and the management of young patients should follow well established pathways.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}